BioLargo’s AOS filter has been repeatedly validated by researchers at the University of Alberta to decontaminate and disinfect water 100 times better, 10 times faster, and at 1/20th the cost of closest competing technology.
BioLargo has been invited to be an NSERC chair member to help decontaminate massive tailings ponds in Canada.
BioLargo sits on this chair along with Suncor, Syncrude, Shell, Canadian Natural Resources, Total, Epcor, Alberta Innovates, Alberta Environment and the University of Alberta.
The AOS Filter is the biggest breakthrough in water treatment in history and will be showcased this August to major industry executives.
The showcase will demonstrate the unprecedented results of the AOS Filter and the data the industry is looking for and will explode share prices.
Walter Schindler just joined BioLargo as a key strategic advisor.
Shares are a steal at anything under $1.00
12 month price target $3
24 month price target $20
They can only sell when Data is released. A lot of them have plans where they automatically sell some when data is released. He probably just wanted to buy something or had bills to pay.
This imbecile shorted CLVS at $50 and shorted BLUE @ $50
So, with the abundance of intelligence.....one would have to assume that the insider selling would be happening knowing the data is good therefore, they're not selling into bad insider knowledge? Any thoughts?
I ma not a poster. This is my first time. I am thinking of buying CLVS. But I was shocked by the insider trading in May, March. What is going on? I'd like to know why before I buy?
Look at CEO Patrick Mahaffey's track record. Each within just a handful of years, NeXtar sold to Gilead, Pharmion sold to Celgene, and now Clovis. Each company developed significant research and pipeline material. Their work has led to important drugs now out there that benefit many, and may even help you someday. Further we investors benefit from sizable profit in the stock market. Win-Win for everyone. Mahaffey's got his ducks in a row, brilliant man.
I am only seeing 9733 shares sold by officers since May 1, 2015. See below. Where are you getting your information??
I am certain that several of you posters are deliberately trying to grip people for your own personal profit.
5/15/15 Barrett Michael Jam...
Director Sale 2,424 91.86 – 92.57 1,141,040 $224.0 K
5/13/15 Spickschen Thorlef
Director Sale 4,309 85.00 – 85.00 30,118 $366.3 K
5/1/15 Mast Erle T
Chief Financial Officer Sale 3,000 81.00 – 83.55 153,583 $245.3 K
What stock are you referring to? This is the Clovis Oncology message board. This stock has been making higher lows and higher highs since 15 October 2014 when it closed at $44.22 per share. At its current pps that is an increase of 11% per MONTH. Not too bad.
Sentiment: Strong Buy
At $150 per share Clovis Oncology's market capitalization is close to $6 billion.
Remember the convertible bond issue has 4 miilion shares behind it. In addition there are the options outstanding to the executives. Everything is in play at $150 per share.
....and I'll continue to hold. Good pipeline news or a buyout. Only a matter of time. At $150 their market cap is still under $5 billion. Pocket link for big Bio or Pharma.
With only a 20 million float, and Billion in revenue coming , I don't see this, at these levels very long. 5-31 is not far away............
Piper Jaffray was making a market in the securities of Clovis Oncology, Inc. at the time this research report was published. Piper Jaffray will buy and sell Clovis Oncology, Inc. securities on a principal basis.